Clinical Effects of Tirzepatide on Kidney Transplant Recipients with Obesity and Type 2 Diabetes

Abstract

【Objective】To clinically analyze the effects of tirzepatide on kidney transplant recipients with obesity and diabetes.【Methods】Kidney recipients with obesity and diabetes who were resistant to diet and exercise therapy were treated with either tirzepatide (TRZ group, n＝22) or liraglutide (LRG group, n＝12). The following data were retrospectively compared between the two groups before and 6 months after treatment: hemoglobin A1c (HbA1c, %), mean blood glucose measured by continuous glucose monitoring (mg/dL), insulin dose (units), body weight changes (kg), serum creatinine (sCr, mg/dL), and urine protein per creatinine (uP/Cr, g/gCr).【Results】In the TRZ group, HbA1c and MBG decreased from 6.5 and 133 before treatment to 5.9 and 113 at 6 months after treatment, respectively, and were significantly lower than those in the LRG group at 6 months. Body weight decreased significantly from 75.6 to 69.5 kg and the decrease in body weight was significantly larger in the TRZ group (-6.25 vs 0.38). The insulin dose was decreased from 26.1 to 16.2 in the TRZ group. sCr and uP/Cr did not show any significant changes in either group.【Conclusions】Tirzepatide effectively improved glucose metabolism and body weight control in kidney recipients with obesity and diabetes.